Back HIV Prevention HIV Vaccines

HIV Vaccines

HIV R4P: RV144 HIV Vaccine's Effects Were Real -- and Could Be Made to Work Better

Findings from further studies using a reformulation of the only HIV vaccine that has ever worked in a large efficacy trial were presented at the recent HIV Research for Prevention conference (HIVR4P) in Cape Town. They showed evidence of stronger antibody responses, and in-depth analysis of these responses suggests that by further developing a similar vaccine, it may be possible to push the immune system to generate an antibody response to HIV that is sufficiently strong to prevent most infections.

alt

Read more:

HIV R4P: The Immunity Project -- An Open-Access T-Cell Vaccine for HIV Infection

Microparticles containing conserved HIV epitopes may be able to prime antigen-presenting dendritic cells, which in turn activate antigen-specific CD8 killer T-cells, offering a potential new approach for developing T-cell-based preventive or therapeutic HIV vaccines, researchers with the open-access Immunity Project reported at the HIV Research for Prevention (HIV R4P) conference last week in Cape Town.

alt

Read more:

HIV R4P: Research for Prevention Conference Opens with Real Hope for HIV Vaccine

"There’s only one Berlin Patient still. But by this time next year he will at least be joined by 40-50 Portland monkeys." These were the words of vaccine researcher Louis Picker, summarizing in quotable form why the outlook for the development of an effective HIV vaccine is brighter than it has been for years, in a satellite session in advance of the HIV Research for Prevention conference (R4P) in Cape Town, South Africa.

alt

Read more:

Coverage of HIV Research for Prevention Conference (HIV R4P)

HIVandHepatitis.com coverage of the HIV Research for Prevention Conference, October 28-31, in Cape Town.

This conference -- combining the previous HIV Vaccines and Microbicides meetings -- includes all aspects of HIV prevention including experimental vaccines, microbicide gels and rings, and pre-exposure prophylaxis (PrEP).

Full listing of coverage by topic

HIV R4P website

11/4/14

alt

HIV Research for Prevention Conference Features Advances in Vaccines, Microbicides, PrEP

The first HIV Research for Prevention -- or HIV R4P -- conference takes place this week in Cape Town, bringing together more than 1300 leading researchers, policymakers, and advocates working on interventions such as HIV vaccines, microbicides, antiretroviral treatment as prevention (TasP), and new forms of pre-exposure prophylaxis (PrEP). The conference incorporates the previously separate HIV vaccine and microbicide meetings as biomedical prevention technologies have converged.

alt

Read more: